Several small molecules, miRNAs, and proteins have been studied as inhibitors of SREBP1 activity in various cancers, which can be repurposed for breast cancer risk reduction, provided that they exhibit sufficient bioavailability and efficacy in the breast. The gene discussed is SREBF1; the disease is breast cancer.